chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Pain in extremity
Clinical narrative: extremely sore left arm; fatigue; lightheaded; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8733), via an unspecified route of administration in the left arm on 26Mar2021 at 04:30 (at the age of 22-years-old), as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies to medications, food or other products. The patient did not take any concomitant medications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 26Mar2021 at 18:00, the patient experienced extremely sore left arm, fatigue and lightheaded. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events and and included treatment with Advil. The clinical outcome of the events pain in left arm, fatigue and dizziness was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Pyrexia, Rash macular, Urticaria, Vaccination site pain
Clinical narrative: Headache; Hives; Red spot all over; Low grade fever; Site was hurting; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown); via unspecified route of administration in the left arm on 26Mar2021 (at the age 56-year-old) at 09:30 as a single dose for COVID-19 immunisation. Medical history included tachycardia, diabetes type 2, asthma, allergy to mold and bee stings. The patient was allergic to pseudoephedrine and Aavelox. Concomitant medication included atenolol (MANUFACTURER UNKNOWN) and budesonide and formoterol fumarate (SYMBICORT) for unknown indication. The patient did not receive any other vaccine within four weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 12:30, the patient experienced headaches, hives, red spots all over, low grade fever and it was also reported that site was hurting. The treatment medication involved the usage of Benadryl. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care visit. The clinical outcome of events headache, hives, red spots all over, low grade fever and site was hurting was resolving at the time of this report. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Myalgia, Nausea
Clinical narrative: muscle pain throughout body; headache; mild nausea; tiredness; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the right arm on 25Mar2021 at 12:30 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history included post herpetic neuralgia and hypothyroidism. The patient had allergies to sulfa drugs. Concomitant medications included gabapentin (MANUFACTURER UNKNOWN) and levothyroxine (MANUFACTURER UNKNOWN) for unknown indication from unknown date. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 25Mar2021 at 19:15, the patient experienced headache, mild nausea, muscle pain throughout body and tiredness. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the adverse events. The clinical outcomes of the events headache, mild nausea, muscle pain throughout body and tiredness were recovered on an unknown date in Mar2021.    No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Oral mucosal eruption, Pain, Pyrexia
Clinical narrative: red rash in the roof of the mouth; Fever; chills; body ache; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199), via an unspecified route of administration in the left arm on 07Mar2021 at 14:15 (at the age of 63-years-old), as a single dose for COVID-19 immunisation. Medical history included G6PD deficiency, COVID-19 and sulfonamide allergy. Concomitant medication included levothyroxine sodium (SYNTHYROID) from unknown date for unspecified indication. The patient previously received acetylsalicylic acid (ASPIRIN) on unknown date for unspecified indication and experienced drug allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19.  On 08Mar2021, next day, the patient experienced fever, chill, body ache and after 6 days on 13Mar2021, the patient experienced red rash in the roof of the mouth that lasted 5 days and was very uncomfortable, never had it before. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcomes of the events fever, chills, body ache was recovered on an unspecified date in Mar2021 and of the event red rash in the roof of the mouth was recovered on 18Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Flushing
Clinical narrative: LT deltoid redness, radiating to LT side of chest; full face flushing; This is a spontaneous report from a contactable other healthcare professional, the patient. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8730), via an unspecified route of administration in the left arm on 23Mar2021 at 13:30 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included breast cancer for which she was on aromatase inhibitor. Concomitant medication included exemestane (MANUFACTURER UNKNOWN), Vitamin d (MANUFACTURER UNKNOWN) and calcium (MANUFACTURER UNKNOWN); all for unknown indication. The patient had a history of allergy to iodine contrast dye. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 23Mar2021 at 14:15, the patient had experienced left deltoid redness which was radiating to left side of chest and full-face flushing. The patient also reported that it lasted approximately for 90 minutes. Adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events left deltoid redness, radiating to left side of chest and full face flushing was resolved on 23Mar2021 at 15:45.  No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, SARS-CoV-2 test
Clinical narrative: Fever; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown), via an unspecified route of administration in the left arm on 19Mar2021( at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient did not take any concomitant medications. The patient had no known allergies to medications, food or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown), via an unspecified route of administration in the left arm on 26Feb2021 at 07:45 ( at the age of 61-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was diagnosed with COVID-19 and since the vaccination the patient had been tested for COVID -19. On 25Mar2021 at 13:00 the patient experienced fever which began 6 days after second injection and now it was over 72 hours with fever. The patient underwent lab tests which included PCR test on 26Mar2021 and tested negative. The clinical outcome of the fever was not recovered.   No follow-up attempts are needed; information about lot/batch number cannot be obtained
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Headache, Hyperhidrosis, Malaise
Clinical narrative: Headache; Overall malaise; Body aches; sweats; Fever; Chills; Nausea; Diarrhea; Rash on left arm; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730) via an unspecified route of administration in the left arm on 18Mar2021 at 21:00 (at the age of 29-years-old) as a single dose for COVID-19 Immunisation. Medical history was reported as thyroid. Concomitant medications included levothyroxine sodium (SYNTHROID) 135mcg received within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination the patient was not diagnosed with COVID-19. Since the vaccination the patient had not been tested for COVID-19. On 26Mar2021 the patient experienced fever, chills, sweats, body aches, nausea, diarrhoea, rash on left arm and on 27Mar2021 the patient was still experiencing fever, headache and overall malaise. No therapeutic measures were taken for the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, chills, sweats, body aches, nausea, diarrhoea, rash on left arm, headache and overall malaise was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain, Pyrexia, Rash
Clinical narrative: Headache; Overall malaise; Body aches; sweats; Fever; Chills; Nausea; Diarrhea; Rash on left arm; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730) via an unspecified route of administration in the left arm on 18Mar2021 at 21:00 (at the age of 29-years-old) as a single dose for COVID-19 Immunisation. Medical history was reported as thyroid. Concomitant medications included levothyroxine sodium (SYNTHROID) 135mcg received within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination the patient was not diagnosed with COVID-19. Since the vaccination the patient had not been tested for COVID-19. On 26Mar2021 the patient experienced fever, chills, sweats, body aches, nausea, diarrhoea, rash on left arm and on 27Mar2021 the patient was still experiencing fever, headache and overall malaise. No therapeutic measures were taken for the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, chills, sweats, body aches, nausea, diarrhoea, rash on left arm, headache and overall malaise was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: U
Vaccine: COVID19
Symptoms: Nail discolouration
Clinical narrative: Fingernail showed black and blue spots; This is a spontaneous report from a contactable healthcare professional, the patient. A 61-year-old patient of unknown gender, received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: UNKNOWN) in the left arm on 14Mar2021 at 12:00 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. The patient's medical history was reported as none and the patient was allergic to epinephrine. Prior to vaccination, the patient was diagnosed with COVID-19 and since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 16Mar2021, 2 days after vaccination, the patient experienced fingernail discoloration, where 3 of the fingernails showed black and blue spots. No therapeutic measures were taken as a result of the event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event fingernail discoloration was not recovered at the time of this report.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Rhinorrhoea
Clinical narrative: continuous runny nose; This is a spontaneous report from a non-contactable consumer, the patient. A 37-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207) via unspecified route of administration in the left arm on 23Mar2021 at 23:45 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. The patient had medical history of lupus, sjogrens syndrome, major depressive disorder and neurological tic disorder. Concomitant medications included hydroxychloroquine (MANUFACTURER UNKNOWN), ZOLOFT, hydroxyzine (MANUFACTURER UNKNOWN), gabapentin (MANUFACTURER UNKNOWN). The patient reported allergies to chamomile and turmeric. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 24Mar2021 at 12:00, the patient experienced continuous runny nose which was reported as a clear, liquid with constant stream. The patient did not receive any treatment measure for the reported events. The adverse event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of event continuous runny nose was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Decreased appetite, Diarrhoea, Fatigue, Migraine
Clinical narrative: Horrible body aches/all over body pain; extreme pain in both hips; severe migraine; nausea; diarrhea; no appetite; Fever; exhaustion; nightmares; skin sensitivity; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727), via an unspecified route of administration in the left arm on 25Mar2021 at 14:15 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Medical history included migraine. Concomitant medication included levothyroxine (MANUFACTURER UNKNOWN), 112 mg, from unknown date for unspecified indication. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE Lot Number: EN6199), via unspecified route of administration in the left arm on 04Mar2021 at 14:30 (at the age of 52-years-old), as a single dose for COVID-19 immunisation and clarithromycin (BIAXIN) on unknown date for unspecified indication and experienced drug allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 26Mar2021 at 04:00, the patient experienced horrible body aches, extreme pain in both hips, severe migraine, nausea, diarrhea, no appetite, fever, exhaustion, nightmares, skin sensitivity, literal all over body pain. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events body aches, pain in both hips, migraine, nausea, diarrhea, no appetite, fever, exhaustion, nightmares and skin sensitivity was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Nightmare, Pain, Pyrexia, Sensitive skin
Clinical narrative: Horrible body aches/all over body pain; extreme pain in both hips; severe migraine; nausea; diarrhea; no appetite; Fever; exhaustion; nightmares; skin sensitivity; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727), via an unspecified route of administration in the left arm on 25Mar2021 at 14:15 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Medical history included migraine. Concomitant medication included levothyroxine (MANUFACTURER UNKNOWN), 112 mg, from unknown date for unspecified indication. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE Lot Number: EN6199), via unspecified route of administration in the left arm on 04Mar2021 at 14:30 (at the age of 52-years-old), as a single dose for COVID-19 immunisation and clarithromycin (BIAXIN) on unknown date for unspecified indication and experienced drug allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 26Mar2021 at 04:00, the patient experienced horrible body aches, extreme pain in both hips, severe migraine, nausea, diarrhea, no appetite, fever, exhaustion, nightmares, skin sensitivity, literal all over body pain. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events body aches, pain in both hips, migraine, nausea, diarrhea, no appetite, fever, exhaustion, nightmares and skin sensitivity was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Ringing in both ears; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER 8732) via an unspecified route of administration in the left arm on 24Mar2021 at 10:45 (at the age of 60-year-old), as a single dose for COVID-19 immunisation. Medical history included Chronic Obstructive Pulmonary Disease (COPD). The patient was allergic to collins, sulpha base and blue berries. Concomitant medications included NAZARETH (unspecified medication) and albuterol inhaler (MANUFACTURER UNKNOWN) for an unknown indication. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient experienced ringing in both ears on 24Mar2021 at 20:30. The patient did not receive treatment for the reported events. The events neither resulted in doctor or other healthcare professional office/clinic visit nor emergency room/department or urgent care. The clinical outcome of ringing in both ears was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Nausea, Vertigo
Clinical narrative: Rolling over in bed, with vertigo.; Im feeling nauseous; headache; headache and intermittent spinning; I also feel tired; This is a spontaneous report from a contactable nurse, the patient. A 64-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: En6206) via an unspecified route of administration in the left arm 11Mar2021(at the age of 64-years-old) at 12:00 as a single dose for COVID-19 immunisation. Medical history included Celiac do (as reported), hypothyroidism and hypertension. The patient was allergic to gluten, avelox and amoxicillin. The concomitant medications included vitamins (unspecified), thyroid medicine (unspecified) and amlodipine (MANUFACTURER UNKNOWN). Prior to vaccination the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines in four weeks prior to COVID-19 vaccination. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021, two weeks after receiving the vaccine, the patient woke up at 02:00 after rolling over in bed, with vertigo. It had been 3 days and the patient was feeling nauseous, had headache with intermittent spinning that stopped only after closing the eyes. The patient also felt tired. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events vertigo, nausea, headache, head spinning and tiredness was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Pain, Pyrexia
Clinical narrative: Chills; Body aches; Fever; Headache; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received a second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3248) via an unspecified route of administration in the left arm on 26Mar2021 at 10:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks of vaccination. The patient did not receive any other medications within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6203) via an unspecified route of administration in the left arm on 03Mar2021 at 11:15 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. On 26Mar2021, 12 hours after vaccination the patient experienced chills, body aches, fever and headache (felt like a sinus headache) that lasted all evening into the following day and all events subsided approximately 24 hours later. The patient did not receive any treatment for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and the emergency room/department or urgent care. The clinical outcome of the events chills, body aches, fever and headache were recovered on 27Mar2021 after the duration of 24 hrs.   No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Pain of skin, Pruritus, Skin swelling
Clinical narrative: itching scalp; sore to touch; A small lump developedon left side of scalp; This is a spontaneous report from a contactable patient. A 55-year-old-non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via unspecified route of administration in the left arm on 26Mar2021 at 15:45 PM (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medication included vitamin D (MANUFACTURER UNKNOWN) and magnesium (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date. The patient did not have allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. Since the vaccination, the patient had not been tested for COVID-19. On 27Mar2021 at 23:45, the patient experienced itching scalp and small lump developed on left side of scalp which was sore to touch. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of events such as itching scalp and small lump developed on left side of scalp which was sore to touch was not recovered at the time of reporting.  No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Neck pain, Pain in extremity, Pruritus
Clinical narrative: Pain in right arm; mild itching all over; neck pain opposite of injection site; joint pain; This is a spontaneous report from a non-contactable consumer, the patient. A 26-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EP7533) via unspecified route of administration in the right arm on 27Mar2021 at 17:45 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history included overweight. Concomitant medications were not reported. It was unknown if the patient had any known allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. On 28Mar2021 at 10:00, the patient experienced pain in right arm, mild itching all over, neck pain opposite of injection site and mild joint pain. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events pain in extremity, pruritus, neck pain and arthralgia were resolving at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Vertigo
Clinical narrative: dizzy/lightheaded/about to faint; head was spinning; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955), via an unspecified route of administration in the left arm on 27Mar2021 at 18:00 (at the age of 63-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medication included atorvastatin (MANUFACTURER UNKNOWN), vitamins (MANUFACTURER UNKNOWN), herbal (MANUFACTURER UNKNOWN); all for unknown indication. The patient did not have allergies to medications, food, or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE Lot Number: EN6199), via unspecified route of administration in the left arm on 06Mar2021 at 18:15 (at the age of 63-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 27Mar2021 at 22:00, 4 hours after the vaccine, the patient had experienced extremely dizzy, lightheaded, where her head was spinning and about to faint. She immediately lay down on kitchen floor. It took many repeats of standing up and lying down for her to move to bedroom, where she stayed for the next few hours. Eventually, the patient was able to prepare for bed but moved slowly and would not fall although the dizzy, light headed feeling was not as intense. 16 hours later, she felt comfortable to move around and did not experience to dizzy feelings. The patient did not receive any treatment for the reported events. Adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events dizzy/light headed/ about to faint and head was spinning was resolved on unknown date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Headache, Myalgia, Paraesthesia, Pyrexia
Clinical narrative: muscle soreness around the injection site.; Headache; Low grade fever; muscle pain; Joint soreness/ Pain; Tingling feeling in both legs; This is a spontaneous report from a contactable consumer, the parent. A 19-year-old female patient received BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) via an unspecified route of administration on 22Mar2021 (at the age of 19_years-old), as a single dose for COVID-19 immunisation. Medical history included environmental allergy (like pollen and dust). Concomitant medication included unspecified immune-tolerance (MANUFACTURER UNKNOWN) therapy for allergy. Prior to vaccination, it was unknown if patient was diagnosed with COVID-19. Since the vaccination, it was unknown if patient had tested for COVID-19. It was unknown if patient received any other vaccines within 4 weeks prior to the COVID vaccine. On 22Mar2021 (within 24 hours), the patient experienced very common side effects or sequelae like muscle soreness around the injection site, headache, low-grade fever, and more generalized muscle; joint soreness or pain and side effect which was most unusual and disturbing was the tingling feeling the patient had (and was still experiencing without any diminution) in both of her legs. It was also reported that, as per doctor the patient was not experiencing any muscle weakness or numbness, then it was not guillainbarre syndrome (GBS), and she should come back if it worsened, but did not prescribe any course of treatment. Therapeutics measure was taken as a result of events vaccination site pain, headache, low grade fever, muscle pain and joint pain which included the treatment with ADVIL (over the counter nonsteroidal anti-inflammatory drug). The adverse event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the events vaccination site pain, headache, low grade fever, muscle pain, pain, joint pain and tingling were not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: muscle soreness around the injection site.; Headache; Low grade fever; muscle pain; Joint soreness/ Pain; Tingling feeling in both legs; This is a spontaneous report from a contactable consumer, the parent. A 19-year-old female patient received BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) via an unspecified route of administration on 22Mar2021 (at the age of 19_years-old), as a single dose for COVID-19 immunisation. Medical history included environmental allergy (like pollen and dust). Concomitant medication included unspecified immune-tolerance (MANUFACTURER UNKNOWN) therapy for allergy. Prior to vaccination, it was unknown if patient was diagnosed with COVID-19. Since the vaccination, it was unknown if patient had tested for COVID-19. It was unknown if patient received any other vaccines within 4 weeks prior to the COVID vaccine. On 22Mar2021 (within 24 hours), the patient experienced very common side effects or sequelae like muscle soreness around the injection site, headache, low-grade fever, and more generalized muscle; joint soreness or pain and side effect which was most unusual and disturbing was the tingling feeling the patient had (and was still experiencing without any diminution) in both of her legs. It was also reported that, as per doctor the patient was not experiencing any muscle weakness or numbness, then it was not guillainbarre syndrome (GBS), and she should come back if it worsened, but did not prescribe any course of treatment. Therapeutics measure was taken as a result of events vaccination site pain, headache, low grade fever, muscle pain and joint pain which included the treatment with ADVIL (over the counter nonsteroidal anti-inflammatory drug). The adverse event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the events vaccination site pain, headache, low grade fever, muscle pain, pain, joint pain and tingling were not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Dizziness postural, Pain
Clinical narrative: Body aches; Weakness; Painful to move; Light headed when standing; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730), via an unspecified route of administration in the left arm, on 27Mar2021 at 12:00 (at the age 25-years-old) as a single dose for COVID-19 immunisation. Medical history included allergies to shellfish and peanuts. Concomitant medication included ethinylestradiol;norgestimate (ESTARYLLA) from unknown date for birth control. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via unspecified route of administration in the left arm, on 25Feb2021 at 16:00 (at the age 25-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 27Mar2021 at 22:45, the patient experienced body aches, weakness, painful to move and light headed when standing. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of the events general body pain, weakness, painful to move and light headed when standing were recovering at the time of this report.   No follow-up attempts are needed. No further information expected.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Sore arm; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: Ep7533) via an unspecified route of administration in the left arm on 27Mar2021 (at the age of 60-years-old) at 14:45 as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date in Mar2021, the patient had experienced sore arm. The clinical outcome of the event sore arm was unknown at the time of the report. No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal pain upper, Back pain, Chest pain, Decreased appetite, Fatigue
Clinical narrative: Extreme vomiting; stomach pain; back pain; Loss of appetite; fatigue; chest pain; This is a spontaneous report received from a contactable consumer, the patient. A 63-Year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) as a single dose via an unspecified route of administration in her right arm on 20Mar2021 at 16:45 (at the age of 63-years-old), as a single dose for COVID-19 immunisation. The patients medical history included kidney stones. The patient had no allergies to medications, food or other products. The patient received hydrochlorothiazide (MANUFACTURER UNKNOWN) for unknown indication medications within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 20Mar2021 at 21:00, the patient experienced extreme vomiting later same day of vaccination, chest pain, stomach pain, back pain, loss of appetite and fatigue. The patient did not receive treatment for the reported events. The events resulted in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome for the events vomiting, chest pain, stomach pain, back pain, loss of appetite and fatigue were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Extreme vomiting; stomach pain; back pain; Loss of appetite; fatigue; chest pain; This is a spontaneous report received from a contactable consumer, the patient. A 63-Year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) as a single dose via an unspecified route of administration in her right arm on 20Mar2021 at 16:45 (at the age of 63-years-old), as a single dose for COVID-19 immunisation. The patients medical history included kidney stones. The patient had no allergies to medications, food or other products. The patient received hydrochlorothiazide (MANUFACTURER UNKNOWN) for unknown indication medications within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 20Mar2021 at 21:00, the patient experienced extreme vomiting later same day of vaccination, chest pain, stomach pain, back pain, loss of appetite and fatigue. The patient did not receive treatment for the reported events. The events resulted in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome for the events vomiting, chest pain, stomach pain, back pain, loss of appetite and fatigue were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Fatigue, Headache, Lymphadenopathy
Clinical narrative: Fever; Chills; vomiting; body aches; wobbly legs and arms/weakness in legs and arms; headache; nausea; lightheaded; Swollen and red and hot at the injection site; Swollen and red and hot at the injection site; Swollen and red and hot at the injection site; fatigue; swollen lymph node in chest; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6208), via unspecified route of administration in the left arm on 22Mar2021 at 15:30 (at the age 53-years-old), as a single dose for COVID-19 immunisation. Medical history included chronic pericarditis. The patient was allergic to penicillin. Concomitant medications included colchicine (MANUFACTURER UNKNOWN) 20 mg, bifidobacterium infantis; lactobacillus acidophilus (PROBIOTIC), fish oil (MANUFACTURER UNKNOWN), multivitamin (MANUFACTURER UNKNOWN); all from unknown dates for unspecified indications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6198); via unspecified route of administration in the left arm on 01Mar2021 at 15:30 (at the age 53-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 22Mar2021 at 20:00, the patient experienced fever, chills, vomiting, body aches, wobbly legs and arms, headache, nausea, light-headed, swollen and red and hot at the injection site, fatigue, weakness in legs and arms and swollen lymph node in chest. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatments for the events. The clinical outcome of the events fever, chills, vomiting, body aches, headache, nausea, lightheaded, vaccination site swelling and vaccination site erythema and vaccination site warmth, fatigue, weakness in legs and arms and swollen lymph node in chest was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Muscular weakness, Nausea, Pain, Pyrexia, Vaccination site erythema
Clinical narrative: Fever; Chills; vomiting; body aches; wobbly legs and arms/weakness in legs and arms; headache; nausea; lightheaded; Swollen and red and hot at the injection site; Swollen and red and hot at the injection site; Swollen and red and hot at the injection site; fatigue; swollen lymph node in chest; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6208), via unspecified route of administration in the left arm on 22Mar2021 at 15:30 (at the age 53-years-old), as a single dose for COVID-19 immunisation. Medical history included chronic pericarditis. The patient was allergic to penicillin. Concomitant medications included colchicine (MANUFACTURER UNKNOWN) 20 mg, bifidobacterium infantis; lactobacillus acidophilus (PROBIOTIC), fish oil (MANUFACTURER UNKNOWN), multivitamin (MANUFACTURER UNKNOWN); all from unknown dates for unspecified indications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6198); via unspecified route of administration in the left arm on 01Mar2021 at 15:30 (at the age 53-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 22Mar2021 at 20:00, the patient experienced fever, chills, vomiting, body aches, wobbly legs and arms, headache, nausea, light-headed, swollen and red and hot at the injection site, fatigue, weakness in legs and arms and swollen lymph node in chest. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatments for the events. The clinical outcome of the events fever, chills, vomiting, body aches, headache, nausea, lightheaded, vaccination site swelling and vaccination site erythema and vaccination site warmth, fatigue, weakness in legs and arms and swollen lymph node in chest was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site swelling, Vaccination site warmth, Vomiting
Clinical narrative: Fever; Chills; vomiting; body aches; wobbly legs and arms/weakness in legs and arms; headache; nausea; lightheaded; Swollen and red and hot at the injection site; Swollen and red and hot at the injection site; Swollen and red and hot at the injection site; fatigue; swollen lymph node in chest; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6208), via unspecified route of administration in the left arm on 22Mar2021 at 15:30 (at the age 53-years-old), as a single dose for COVID-19 immunisation. Medical history included chronic pericarditis. The patient was allergic to penicillin. Concomitant medications included colchicine (MANUFACTURER UNKNOWN) 20 mg, bifidobacterium infantis; lactobacillus acidophilus (PROBIOTIC), fish oil (MANUFACTURER UNKNOWN), multivitamin (MANUFACTURER UNKNOWN); all from unknown dates for unspecified indications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6198); via unspecified route of administration in the left arm on 01Mar2021 at 15:30 (at the age 53-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 22Mar2021 at 20:00, the patient experienced fever, chills, vomiting, body aches, wobbly legs and arms, headache, nausea, light-headed, swollen and red and hot at the injection site, fatigue, weakness in legs and arms and swollen lymph node in chest. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatments for the events. The clinical outcome of the events fever, chills, vomiting, body aches, headache, nausea, lightheaded, vaccination site swelling and vaccination site erythema and vaccination site warmth, fatigue, weakness in legs and arms and swollen lymph node in chest was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness
Clinical narrative: I have been feeling dizzy since the second day after receiving the vaccine.; This is a spontaneous report received from a contactable consumer, the patient. A 60-year-old male patient received his first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207) via an unspecified route of administration in the left arm on 21Mar2021 at 12:30 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history were reported as sleep apnea, acid reflux and high cholesterol. Concomitant medication was reported as none. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient had not received any other vaccines within four weeks prior to the COVID vaccine. On 23Mar2021 at 18:00, it was reported as the patient felt dizzy since the second day after the vaccine was received. The adverse event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The treatment received for the adverse event was reported as no. The clinical outcome of the event dizzy was recovering at the time of this report.    No follow-up attempts are needed. No further information is expected.